Novo Nordisk A/S: Novo Nordisk A/S - Share repurchase programme

December 12, 2011 09:41 ET | Source: Novo Nordisk A/S Novo Nordisk A/S

For release content, please refer to the attachment.

Attachments

Company Announcement no 78 / 2011

Company Announcement no 78 / 2011...

Recommended Reading

September 18, 2026 06:36 ET | Source: Novo Nordisk A/S

Novo’s once-weekly Sogroya® (somapacitan) receives positive CHMP opinion in Europe for children with idiopathic short stature (unexplained shortness)

Novo Nordisk receives positive opinion from the CHMP of the EMA, recommending once-weekly Sogroya® for children with idiopathic short stature
Read More
September 17, 2026 10:14 ET | Source: Novo Nordisk A/S

Novo: CHMP recommends EU approval of FREHEMGO® (denecimig), the first factor VIIIa mimetic offering monthly, once every two weeks and weekly dosing in a pre-filled pen, for the treatment of haemophilia A

EMA has adopted a positive opinion recommending marketing authorisation for FREHEMGO® (denecimig) to treat haemophilia A (HA), with or without inhibitors
Read More